大葉大學圖書館 |

Optimization of pharmaceutical R&D programs and portfolios[electronic resource] :design and investment strategy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	338.476151
書名/作者:	Optimization of pharmaceutical R&D programs and portfolios : design and investment strategy // edited by Zoran Antonijevic.
其他作者:	Antonijevic, Zoran.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	viii, 202 p. : : ill. (some col.), digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Pharmaceutical industry - Technological innovations
標題:	Drugs - Research.
標題:	Drugs - Design.
標題:	Economics/Management Science.
標題:	Operation Research/Decision Theory.
標題:	Optimization.
標題:	Statistics for Life Sciences, Medicine, Health Sciences.
ISBN:	9783319090757 (electronic bk.)
ISBN:	9783319090740 (paper)
內容註:	Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.
摘要、提要註:	Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio's value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria. This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader.
電子資源:	http://dx.doi.org/10.1007/978-3-319-09075-7

Optimization of pharmaceutical R&D programs and portfolios[electronic resource] :design and investment strategy /
Optimization of pharmaceutical R&D programs and portfoliosdesign and investment strategy /[electronic resource] :edited by Zoran Antonijevic. - Cham :Springer International Publishing :2015. - viii, 202 p. :ill. (some col.), digital ;24 cm.

Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio's value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria. This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader.

ISBN: 9783319090757 (electronic bk.)

Standard No.: 10.1007/978-3-319-09075-7doiSubjects--Topical Terms:

603095
Pharmaceutical industry
--Technological innovations

LC Class. No.: HD9665.5

Dewey Class. No.: 338.476151

Optimization of pharmaceutical R&D programs and portfolios[electronic resource] :design and investment strategy /
LDR:03512nam a2200325 a 4500 001 424848
003 DE-He213
005 20150610114932.0
006 m d
007 cr nn 008maaau
008 151119s2015 gw s 0 eng d
020 $a 9783319090757 (electronic bk.)
020 $a 9783319090740 (paper)
024 7 $a 10.1007/978-3-319-09075-7 $2 doi
035 $a 978-3-319-09075-7
040 $a GP $c GP
041 0 $a eng
050 4 $a HD9665.5
072 7 $a KJT $2 bicssc
072 7 $a KJMD $2 bicssc
072 7 $a BUS049000 $2 bisacsh
082 0 4 $a 338.476151 $2 23
090 $a HD9665.5 $b .O62 2015
245 0 0 $a Optimization of pharmaceutical R&D programs and portfolios $h [electronic resource] : $b design and investment strategy / $c edited by Zoran Antonijevic.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a viii, 202 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.
520 $a Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio's value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria. This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader.
650 0 $a Pharmaceutical industry $x Technological innovations $x Management. $3 603095
650 0 $a Drugs $x Research. $3 587773
650 0 $a Drugs $x Design. $3 424032
650 1 4 $a Economics/Management Science. $3 463465
650 2 4 $a Operation Research/Decision Theory. $3 511310
650 2 4 $a Optimization. $3 463683
650 2 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 464109
700 1 $a Antonijevic, Zoran. $3 603094
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-09075-7
950 $a Business and Economics (Springer-11643)